AOD9604, MOTS-c, and tesamorelin appear together in peptide blends sold for research. Learn how each compound works, common dosages, and safety notes.
AOD9604, MOTS-c, and tesamorelin are three chemically unrelated peptides that vendors package together as a single research blend marketed for fat loss and metabolic research. Tesamorelin is an FDA-approved GHRH analog, AOD9604 is a modified fragment of human growth hormone, and MOTS-c is a mitochondrial-derived peptide. No combination product containing all three is FDA-approved, and no published human trial has tested them together as a blend.
What Is in an AOD9604, MOTS-c, and Tesamorelin Blend?
Vendors typically sell the aod mots-c tesamorelin blend as one lyophilized vial that the buyer reconstitutes with bacteriostatic water. The three compounds are grouped because all of them appear in metabolic and body-composition research, not because they share a mechanism or a target tissue.
- AOD9604 — a 16-amino-acid fragment of human growth hormone covering the 176–191 region, with a tyrosine added for stability.
- MOTS-c — a 16-amino-acid mitochondrial-derived peptide encoded in the mitochondrial 12S rRNA region.
- Tesamorelin — a 44-amino-acid growth hormone–releasing hormone (GHRH) analog that acts on the pituitary.
Buyers searching for an aod-9604 mots-c tesamorelin stack should know that no manufacturer publishes a validated blend ratio and no trial has compared one ratio against another. Most product pages list only total peptide mass per vial, not the amount of each individual compound.
How Each Peptide Works
AOD9604
AOD9604 was engineered to mimic the fat-metabolizing portion of growth hormone while avoiding the parts that raise IGF-1 and affect blood sugar. Early human studies examined changes in fat mass, and the compound was never approved for weight loss. AOD9604 is not FDA-approved for any human indication.
MOTS-c
MOTS-c is studied for its role in cellular energy sensing, insulin sensitivity, and glucose handling. Much of the data comes from animal models and cell cultures, with some researchers describing an exercise-mimetic effect. MOTS-c has no approved human use and remains an early-stage research peptide.
Tesamorelin
Tesamorelin is the only one of the three with FDA approval, and that approval is narrow. It is sold as Egrifta for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy, and it works by stimulating pituitary growth hormone release, which raises IGF-1. Tesamorelin is not approved for general weight loss in people without HIV.
The tesamorelin vs aod9604 comparison comes down to hormone activity: tesamorelin raises growth hormone and IGF-1, while AOD9604 was designed to act on fat metabolism without those effects. In the mots-c vs aod9604 question, MOTS-c is studied mainly for cellular energy regulation and insulin sensitivity rather than direct fat breakdown.
AOD9604 vs MOTS-c vs Tesamorelin at a Glance
| Compound | Class | Main Research Focus | Raises IGF-1? | FDA Status |
|---|---|---|---|---|
| AOD9604 | Modified GH fragment | Fat metabolism | No, by design | Not approved |
| MOTS-c | Mitochondrial-derived peptide | Insulin sensitivity, energy metabolism | No evidence | Not approved |
| Tesamorelin | GHRH analog | Visceral fat in HIV lipodystrophy | Yes | Approved (Egrifta) |
Reported Dosage Ranges and Blend Ratios
Anyone looking up an aod 9604 mots-c tesamorelin dosage will find numbers circulating on forums rather than in controlled blend trials. The figures below come from single-compound studies and product labeling, not from testing the combination.
| Compound | Commonly Cited Dose | Route | Frequency |
|---|---|---|---|
| Tesamorelin | 1–2 mg per day (label dose is 2 mg) | Subcutaneous injection | Daily |
| AOD9604 | 250–500 mcg per day | Subcutaneous injection | Daily, sometimes split |
| MOTS-c | 5–10 mg per week | Subcutaneous injection | 2–3 times weekly |
These numbers describe how each peptide was dosed alone, in a specific study population, under research conditions. They are not a recommendation, and a tesamorelin and mots-c stack has never been evaluated for safety in a clinical trial.
Blend ratios deserve more skepticism than they usually get. A vial labeled as a 10 mg blend may contain wildly different proportions of each peptide, and the label often does not disclose them.
Safety, Sourcing, and Legal Status
Most of these products are sold with a research-use-only label, which means the seller explicitly states they are not for human consumption. That label shifts legal responsibility to the buyer and offers no guarantee of sterility, purity, or accurate dosing.
- Hormone effects: Tesamorelin raises IGF-1 and growth hormone, which can affect fluid balance, glucose, and joint comfort.
- Injection risks: Poorly filtered or non-sterile vials carry infection and injection-site reaction risks.
- Purity: A third-party certificate of analysis is not the same as an independent audit, and some certificates are falsified.
- Legal status: Tesamorelin requires a prescription in the United States; AOD9604 and MOTS-c are not approved drugs.
Anyone considering any of these compounds should talk with a licensed healthcare professional rather than relying on vendor marketing or forum protocols. People who are pregnant, breastfeeding, taking diabetes medication, or managing a hormone-sensitive condition face higher risk.
What the Research Does Not Show
No published study has compared AOD9604, MOTS-c, and tesamorelin in a combined protocol, and no evidence shows that blending them produces additive fat loss. Most AOD9604 and MOTS-c data come from animal models or small early studies, while tesamorelin's human data come from HIV-associated lipodystrophy populations that may not generalize to healthy adults.
Combining three peptides also makes it impossible to attribute any effect or side effect to a single compound. A user who experiences a reaction cannot easily tell which ingredient caused it, which complicates both self-assessment and any clinical evaluation.
The bottom line: the aod9604 mots c tesamorelin blend is a vendor category, not a studied therapy. Each peptide has its own evidence base, and that evidence does not transfer automatically to a combined product.
Frequently Asked Questions
Is an AOD9604, MOTS-c, and tesamorelin blend FDA-approved?
No. Tesamorelin is the only one of the three with FDA approval, and it is approved only as Egrifta for HIV-associated lipodystrophy, not for general weight loss. AOD9604 and MOTS-c are not FDA-approved for any human use, and no combination product containing all three has been reviewed by the agency.
What is a typical AOD9604, MOTS-c, and tesamorelin dosage?
There is no established dosage for the blend because it has never been tested in a clinical trial. Single-compound research and labeling cite roughly 1–2 mg daily for tesamorelin, 250–500 mcg daily for AOD9604, and 5–10 mg weekly for MOTS-c. Those figures are not a recommendation and should not be treated as a safe protocol.
Can you stack tesamorelin with AOD9604 and MOTS-c?
People combine them in informal protocols, but no human trial has evaluated the three together, so the safety and interaction profile is unknown. Tesamorelin raises IGF-1 and growth hormone, while AOD9604 and MOTS-c do not, so the blend mixes compounds with very different hormonal effects. Discuss any peptide use with a licensed healthcare professional before starting.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.